Never miss an update from Yeda
Create your free account to connect with Yeda and thousands of other innovative organizations and professionals worldwide
The serum metabolome contains a plethora of biomarkers and causative agents of various diseases. They are known to be modulated by various genetic and environmental factors such as the gut microbiome, nutrition, and lifestyle. However, most of the serum metabolites and their determinants are still unknown. The group of Prof. Eran Segal characterized the serum metabolome of a well-phenotyped human cohort using mass spectrometry. Using this database, the team developed machine learning algorithms to predict metabolite levels in held-out individuals based on their host genetics, gut microbiome, clinical parameters, diet, lifestyle, and anthropometric measurements. The team developed a method to predict the serum metabolome non-invasively, based on the subject’s microbiome profile (using stool samples) or dietary habits. The method could be applied to predict diseases associated with specific blood metabolites (i.e., metabolic disease, cardiovascular disease, and kidney disease). It can also provide recommendations for dietary changes, probiotics, or antibiotics consumption to alter the blood metabolome and improve a subject’s health.
Background and Unmet Need
The blood contains many small molecules called the serum metabolome, which are either produced by the body or taken up from the environment. Some of these metabolites are known as predictive diagnostic biomarkers and, in some cases, even as causal agents in disease development. For example, high cholesterol levels lead to plaque accumulation in blood vessels, increasing heart attack and stroke risk. Therefore, high blood cholesterol is both a diagnostic marker for cardiovascular diseases and a therapeutic target for drugs such as statins. Similarly, high blood sugar is a well-known marker for type II diabetes. Previous studies indicated that human genetics account for less than 7% of the serum metabolites, suggesting major contributions from environmental factors. Additional factors that were previously shown to actively modulate serum metabolites are the gut microbiome, nutrition (dietary patterns such as red meat, whole-grain bread, tea, and coffee), and smoking.
Despite the wealth of potential biomarkers and therapeutic targets found in the blood, most of the serum metabolites and their determinants are still unknown.
The Solution
Prof. Eran Segal and his team used a single, well phenotyped, healthy human cohort, quantified all their serum metabolites, and applied machine-learning algorithms to predict metabolite levels in held-out individuals based on host genetics, gut microbiome, clinical parameters, diet, lifestyle, and anthropometric measurements.1
Based on their findings, the team developed a method to predict the quantity of metabolites in the blood based on a subject’s gut microbiome profile or food consumption habits.
Technology Essence
Prof. Eran Segal and his team measured the levels of 1,251 metabolites (using mass spectrometry) in serum samples from a unique and deeply phenotyped healthy human cohort of 491 individuals2. They applied machinelearning algorithms to predict metabolite levels in held-out individuals based on host genetics, gut microbiome, clinical parameters, diet, lifestyle, and anthropometric measurements and obtained statistically significant predictions for more than 76% of the profiled metabolites (Figure 1). Diet and gut microbiome had the strongest predictive power, as each of them independently explains a wide range of biochemicals. The team validated their microbiome-related predictions by showing a high replication rate in two geographically independent cohorts. To support the causality of these predictions, the team showed that some metabolites that were predicted to be positively associated with bread, indeed increased in levels following a randomized clinical trial of bread intervention.
Therefore, the present technology offers a method to predict blood metabolites based on a subject’s microbiome profile or diet. Moreover, the predicted metabolome can be used for diagnosing diseases that are associated with specific metabolites, such as metabolic disease, cardiovascular disease, and kidney disease. This method can also be used to aid in altering the blood metabolite composition of a subject, either by dietary recommendations, probiotic or antibiotic consumption.
Applications and Advantages
Development Status
Prof. Segal and his team created machine learning procedures for predicting blood metabolites profiles based on microbiome or food consumption habits. They validated the robustness and reproducibility of the models based on gut microbiome data by applying them to two geographically independent cohorts. As a proof of concept for clinical relevance, the team showed that metabolites that were predicted by their model to be positively associated with bread consumption were found to increase after a randomized clinical trial of bread intervention (Figure 2). This demonstrated that the interactions observed by the model could be causal and can be used for clinical assessments.
Figure 1 - Diet, gut microbiome, genetics and clinical data predict the levels of most serum metabolites. a, Box and swarm plots (centre, median; box, interquartile range (IQR); whiskers, 1.5 × IQR) showing the explained variance (EV; R2) of the top 50 significantly predicted metabolites (when available) of each feature group. b, Heat map with colour gradient from left to right corresponding to the 95% confidence interval for the EV, for each metabolite by every feature group. The number of metabolites per group is shown in brackets. c, Enrichment of metabolite types in the predictions by each feature group. Only significant enrichments are shown. Exact P values are written in each cell.
Figure 2 - Increases in levels of metabolites explained by bread after an intervention of increased bread consumption. a, Schematic of the measurement of metabolites and of white bread and whole wheat bread consumption. The prediction models were constructed using samples from distinct participants who consumed and recorded their normal diet for one week (n = 458 participants). In a randomized controlled trial3 participants increased their consumption of either wholegrain sourdough bread or industrial white bread (n=10). b, Histogram of directional mean absolute SHAP values of whole wheat bread consumption for metabolites computed on the basis of held-out samples from our cohort. The top 5% (n = 59; blue) positively associated metabolites and the top 5% (n = 59; red) negatively associated metabolites are used for further analysis. c, Box plots showing the mean fold change in the top 5% positively (blue) and negatively (red) associated metabolites, separated by intervention group. They show a significantly higher mean fold change for the top 5% positively associated metabolites compared with the top 5% negatively associated metabolites under the sourdough bread intervention (two-sided Mann–Whitney U-test, P = 5 × 10?11). d, e, The fold changes of metabolite levels for both betaine (d; P=0.0036) and cytosine (e; P=0.0014) were higher in the sourdough bread group compared to the white bread group.
References
1. The IMI DIRECT consortium, Bar N, Korem T, et al. A reference map of potential determinants for the human serum metabolome. Nature. 2020;588(7836):135-140. doi:10.1038/s41586-020-2896-2 [1]
2. Zeevi D, Korem T, Zmora N, et al. Personalized Nutrition by Prediction of Glycemic Responses. Cell. 2015;163(5):1079-1094. doi:10.1016/j.cell.2015.11.001 [2]
3. Korem T, Zeevi D, Zmora N, et al. Bread Affects Clinical Parameters and Induces Gut Microbiome-Associated Personal Glycemic Responses. Cell Metab. 2017;25(6):1243-1253.e5. doi:10.1016/j.cmet.2017.05.002 [3]
Yeda ("Knowledge" in Hebrew) Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science (WIS) and is the second company of its kind established in the world.
WIS is one of the world’s leading multidisciplinary basic research institutions in the natural and exact sciences. It is located in Rehovot, Israel, just south of Tel Aviv. It was initially established as the Daniel Sieff Institute in 1934, by Israel and Rebecca Sieff of London in memory of their son Daniel. In 1949, it was renamed for Dr. Chaim Weizmann, the first President of the State of Israel and Founder of the Institute.
Yeda initiates and promotes the transfer to the global marketplace of research findings and innovative technologies developed by WIS scientists. Yeda holds an exclusive agreement with WIS to market and commercialize its intellectual property and generate income to support further research and education.
Since 1959 Yeda has generated the highest income per researcher compared to any other TTO worldwide. Weizmann has generated a number of groundbreaking therapies, such as Copaxone, Rebif, Tookad, Erbitux, Vectibix, Protrazza, Humira, and recently the CAR-T cancer therapy Yescarta.
Yeda performs the following activities:
◣ Identifies and assesses research projects with commercial potential.
◣ Protects the intellectual property of WIS and its scientists.
◣ Licenses WIS' inventions and technologies to industry.
◣ Establishes new Startup companies based in WIS Intellectual Property
◣ Channels funding from industry to research projects.
Our portfolio covers a broad spectrum of the natural sciences, including:
◣ Agriculture and Plant Genetics, including Bio-fuels
◣ Chemistry and Nanotechnology
◣ Environmental Sciences and Solar Energy
◣ Mathematics and Computer Science
◣ Medical Devices
◣ Pharmaceuticals and Diagnostics
◣ Physics and Electro-Optics
◣ Research Tools
Create your free account to connect with Yeda and thousands of other innovative organizations and professionals worldwide
Send a request for information
to Yeda
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support